Affiliation:
1. Department of Internal medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
2. Department of Radiology, Asan Medical Center, Seoul, South Korea
3. Department of Radiology, Seoul National University Bundang Hospital, Seongnam, South Korea
4. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Abstract
We aimed to evaluate the distribution of small-bowel involvement in Crohn’s disease (CD) and its association with clinical outcomes. This study included CD patients who underwent computed tomography (CT) at initial diagnosis from June 2006 to April 2021. Two abdominal radiologists reviewed the CT images, and independently rated the presence of “bowel wall thickening,” “stricture,” and “fistula or abscess” in the small bowel segments of jejunum, distal jejunum/proximal ileum, distal ileum, and terminal ileum, respectively. Based on findings of the image review, each patient’s “disease-extent imaging score” and “behavior-weighted imaging score” (a higher score indicative of more structuring or penetrating disease) were calculated. Major clinical outcomes (emergency department [ED] visit, operation, and use of corticosteroids or biologics) were compared according to the 2 scores and L4 involvement by the Montreal classification. The proportions of involvement in the jejunum, distal jejunum/proximal ileum, distal ileum, and terminal ileum were 2.0%, 30.3%, 82.2%, and 71.7%, respectively, identifying 30.3% of patients as having L4 disease and 69.7% of patients as having involvement of multiple segments. Clinical outcomes were not significantly associated with the disease-extent imaging score or L4 involvement. However, significant differences were noted for the ED visits and the use of biologics, according to the behavior-weighted imaging score. Moreover, in multivariable analysis, disease behavior was the only factor associated with all clinical outcomes (ED visit, hazard ratio [HR] 2.127 [1.356–3.337], P = .001; operation, HR 8.216 [2.629–25.683], P < .001; use of corticosteroid, HR 1.816 [1.249–2.642], P = .002; and use of biologics, HR 2.352 [1.492–3.708], P < .001). Initial disease behavior seems to be a more critical factor for clinical outcomes of CD than the extent or distribution of small-bowel involvement on CT.
Publisher
Ovid Technologies (Wolters Kluwer Health)